For research use only. Not for therapeutic Use.
Vem-bisamide-2(CAT: I037999) is a derivative of vemurafenib, a selective inhibitor of the BRAFV600E mutant kinase, widely utilized in oncology research. This compound is designed to target mutated BRAF signaling pathways, which are critical in the progression of certain cancers, including melanoma and thyroid cancer. Vem-bisamide-2 provides enhanced pharmacological insights into kinase inhibition and resistance mechanisms associated with BRAF-targeted therapies. Researchers use it to investigate the therapeutic potential and molecular mechanisms underlying BRAFV600E-driven malignancies. With its specificity and advanced design, Vem-bisamide-2 serves as a valuable tool for preclinical studies aimed at developing next-generation targeted cancer therapies.
Catalog Number | I037999 |
Synonyms | Vem-bisamide-2; Vemurafenib dimer, PLX4032 dimer; PLX-4032 dimer; PLX 4032 dimer; RG7204 dimer; RG-7204 dimer ; RG 7204 dimer ; RO5185426 dimer |
Molecular Formula | C52H50F4N8O9S2 |
Purity | 98% |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | 2,2'-oxybis(N-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)acetamide) |
InChI | InChI=1S/C52H50F4N8O9S2/c1-3-17-74(69,70)63-41-15-13-39(53)45(47(41)55)49(67)37-25-61-51-35(37)19-33(23-59-51)31-9-5-29(6-10-31)21-57-43(65)27-73-28-44(66)58-22-30-7-11-32(12-8-30)34-20-36-38(26-62-52(36)60-24-34)50(68)46-40(54)14-16-42(48(46)56)64-75(71,72)18-4-2/h5-16,19-20,23-24,37-38,63-64H,3-4,17-18,21-22,25-28H2,1-2H3,(H,57,65)(H,58,66)(H,59,61)(H,60,62) |
InChIKey | OQHNUZDJTPNINN-UHFFFAOYSA-N |
SMILES | FC1=CC=C(NS(CCC)(=O)=O)C(F)=C1C(C2CNC3=C2C=C(C4=CC=C(CNC(COCC(NCC(C=C5)=CC=C5C6=CC7=C(N=C6)NCC7C(C8=C(F)C(NS(CCC)(=O)=O)=CC=C8F)=O)=O)=O)C=C4)C=N3)=O |